Investigational drug reduces high potassium levels in chronic kidney disease patients

Research published today found that the investigational drug patiromer decreased high potassium levels and maintained normal potassium levels in patients with chronic kidney disease. The results of a multicenter trial appear in the New England Journal of Medicine.

Elevated potassium, a condition called , increases the risk of death in high-risk patients and limits the use of several types of drugs, called RAAS (renin-angiotensin-aldosterone system) inhibitors, commonly used to control hypertension and and prevent kidney disorders.

"Patients with advanced are at highest risk for hyperkalemia thanks to a double whammy," says the study's principal investigator, Matthew R. Weir, MD, professor of medicine and director of the Division of Nephrology at the University of Maryland School of Medicine. "Their kidneys are unable to remove potassium from the body effectively, and the patient may also be taking certain blood pressure control drugs that have been linked to high potassium levels. Current medications for hyperkalemia have gastrointestinal side effects that limit their extended use. We hoped the drug in this study would do the job with minimal side effects."

In this Phase 3 study of 237 patients with who were receiving RAAS inhibitors, 76 percent of the patients reached the target potassium level after four weeks on patiromer. Subsequently, 107 patients were randomly assigned to the drug or a placebo. The potassium level increase was greater in the placebo group than with patiromer, and elevated potassium recurred in 60 percent of the compared to 15 percent of the patiromer group through week eight. Mild-to-moderate constipation was the most common adverse event.

Explore further

Drug lowers high potassium levels associated with potentially lethal cardiac arrhythmias

Journal information: New England Journal of Medicine

Citation: Investigational drug reduces high potassium levels in chronic kidney disease patients (2014, November 21) retrieved 19 October 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more